Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Director | September 06, 2024 | September 09, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEXX LABORATORIES INC /DE
Report date September 06, 2024 · Filed September 09, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,651 |
Reported balance
After 2024-09-06 transaction · row 1
1 source rowRow 1 · 2024-09-06 · Gift · Disposed 230,000 · Balance 35,651 |
| Common StockSEC Table I · non-derivative | Indirectby Jonathan W. Ayers 2022 GRAT | 0 |
Reported balance
After 2024-09-06 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-09-06 · Gift · Disposed 302,179 · Balance 0 F1: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2022 GRAT ('2022 GRAT'). The 2022 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Indirectby Jonathan W. Ayers 2024 GRAT | 419,574 |
Reported balance
After 2024-09-06 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2024-09-06 · Gift · Acquired 419,574 · Balance 419,574 F2: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2024 GRAT ('2024 GRAT'). The 2024 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Indirectby Ayers Family Trust | 122,605 |
Reported balance
After 2024-09-06 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2024-09-06 · Gift · Acquired 112,605 · Balance 122,605 |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2022 GRAT ('2022 GRAT'). The 2022 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F2: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2024 GRAT ('2024 GRAT'). The 2024 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 06, 2024 Filed Sep 9, 2024 20:20 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 112,605 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000132 · wk-form4_1725913212.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · by Ayers Family Trust Disclosed balance after: 122,605 Read SEC document |
| September 06, 2024 Filed Sep 9, 2024 20:20 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 419,574 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000132 · wk-form4_1725913212.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · by Jonathan W. Ayers 2024 GRAT Disclosed balance after: 419,574 F2 · ownership.nature: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2024 GRAT ('2024 GRAT'). The 2024 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 06, 2024 Filed Sep 9, 2024 20:20 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 302,179 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000132 · wk-form4_1725913212.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · by Jonathan W. Ayers 2022 GRAT Disclosed balance after: 0 F1 · ownership.nature: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2022 GRAT ('2022 GRAT'). The 2022 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 06, 2024 Filed Sep 9, 2024 20:20 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 230,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000132 · wk-form4_1725913212.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,651 Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 257 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000096 · wk-form4_1715209202.xml · derivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 257 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier. Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 262 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000096 · wk-form4_1715209202.xml · derivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262 Underlying: Common Stock · 262 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 609 | $0.00 Strike: $476.87 | $0.00 |
DisclosureSEC source: 0000874716-24-000096 · wk-form4_1715209202.xml · derivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 609 Underlying: Common Stock · 609 shares Expires 2034-05-05 F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 257 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000096 · wk-form4_1715209202.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,651 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 22:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 5,350 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000019 · wk-form4_1707775381.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,394 Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 22:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 850 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000016 · wk-form4_1707516169.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,744 Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000016 · wk-form4_1707516169.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,594 Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 2,424 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-23-000140 · wk-form4_1701900002.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 272,594 Read SEC document |
| November 29, 2023 Filed Dec 1, 2023 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 1,850 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-23-000137 · wk-form4_1701468002.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,018 Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 2,506 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-23-000135 · wk-form4_1700690405.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,868 Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 23:50 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 2,494 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-23-000133 · wk-form4_1700178604.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 279,374 Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 147,821 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-23-000123 · wk-form4_1694206826.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,868 Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 147,821 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-23-000123 · wk-form4_1694206826.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · by Jonathan W. Ayers 2022 GRAT Disclosed balance after: 302,179 F1 · ownership.nature: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2022 GRAT (the 'GRAT'). The GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 250 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-23-000116 · wk-form4_1693947610.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,047 Read SEC document |
| August 31, 2023 Filed Sep 5, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-23-000116 · wk-form4_1693947610.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,297 Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 23:37 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 492 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-23-000111 · wk-form4_1692315455.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,547 Read SEC document |
| August 11, 2023 Filed Aug 14, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-23-000109 · wk-form4_1692046804.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,039 Read SEC document |
| May 19, 2023 Filed May 22, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 10,000 | Not disclosed Strike: $79.54 | Not disclosed |
DisclosureSEC source: 0000874716-23-000086 · wf-form4_168478920867596.xml · derivative · entry 22 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,540 Underlying: Common Stock · 10,000 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F19 · price: Not applicable. F18 · derivative.exercise_date: Grant of option to buy 74,316 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| May 19, 2023 Filed May 22, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 300 | $498.48 | $149,544.00 |
DisclosureSEC source: 0000874716-23-000086 · wf-form4_168478920867596.xml · nonDerivative · entry 18 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,039 F16 · price: Represents the weighted average price of the shares sold ranging from a low of $498.47 to a high of $498.50 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 19, 2023 Filed May 22, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 759 | $497.66 | $377,720.60 |
DisclosureSEC source: 0000874716-23-000086 · wf-form4_168478920867596.xml · nonDerivative · entry 17 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,339 F15 · price: Represents the weighted average price of the shares sold ranging from a low of $497.00 to a high of $497.99 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 19, 2023 Filed May 22, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 886 | $495.94 | $439,398.50 |
DisclosureSEC source: 0000874716-23-000086 · wf-form4_168478920867596.xml · nonDerivative · entry 16 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,098 F14 · price: Represents the weighted average price of the shares sold ranging from a low of $495.53 to a high of $496.45 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 19, 2023 Filed May 22, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,229 | $494.28 | $607,465.20 |
DisclosureSEC source: 0000874716-23-000086 · wf-form4_168478920867596.xml · nonDerivative · entry 15 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,984 F13 · price: Represents the weighted average price of the shares sold ranging from a low of $493.37 to a high of $494.53 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 19, 2023 Filed May 22, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,426 | $492.82 | $702,756.61 |
DisclosureSEC source: 0000874716-23-000086 · wf-form4_168478920867596.xml · nonDerivative · entry 14 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,213 F12 · price: Represents the weighted average price of the shares sold ranging from a low of $492.38 to a high of $493.31 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 19, 2023 Filed May 22, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 400 | $491.59 | $196,636.00 |
DisclosureSEC source: 0000874716-23-000086 · wf-form4_168478920867596.xml · nonDerivative · entry 13 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,639 F11 · price: Represents the weighted average price of the shares sold ranging from a low of $491.36 to a high of $491.74 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 19, 2023 Filed May 22, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 300 | $490.03 | $147,008.49 |
DisclosureSEC source: 0000874716-23-000086 · wf-form4_168478920867596.xml · nonDerivative · entry 12 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,039 F10 · price: Represents the weighted average price of the shares sold ranging from a low of $489.865 to a high of $490.11 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 19, 2023 Filed May 22, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,308 | $488.77 | $639,317.44 |
DisclosureSEC source: 0000874716-23-000086 · wf-form4_168478920867596.xml · nonDerivative · entry 11 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,339 F9 · price: Represents the weighted average price of the shares sold ranging from a low of $488.41 to a high of $489.35 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 19, 2023 Filed May 22, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,254 | $487.82 | $1,099,539.29 |
DisclosureSEC source: 0000874716-23-000086 · wf-form4_168478920867596.xml · nonDerivative · entry 10 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,647 F8 · price: Represents the weighted average price of the shares sold ranging from a low of $487.34 to a high of $488.32 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 19, 2023 Filed May 22, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,138 | $486.92 | $554,116.21 |
DisclosureSEC source: 0000874716-23-000086 · wf-form4_168478920867596.xml · nonDerivative · entry 9 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,901 F7 · price: Represents the weighted average price of the shares sold ranging from a low of $486.29 to a high of $487.27 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 19, 2023 Filed May 22, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 10,000 | $79.54 | $795,400.00 |
DisclosureSEC source: 0000874716-23-000086 · wf-form4_168478920867596.xml · nonDerivative · entry 8 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2023 Filed May 22, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 10,000 | Not disclosed Strike: $79.54 | Not disclosed |
DisclosureSEC source: 0000874716-23-000086 · wf-form4_168478920867596.xml · derivative · entry 21 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,540 Underlying: Common Stock · 10,000 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F19 · price: Not applicable. F18 · derivative.exercise_date: Grant of option to buy 74,316 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| May 18, 2023 Filed May 22, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,298 | $491.91 | $638,493.73 |
DisclosureSEC source: 0000874716-23-000086 · wf-form4_168478920867596.xml · nonDerivative · entry 7 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,039 F6 · price: Represents the weighted average price of the shares sold ranging from a low of $491.54 to a high of $492.345 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 18, 2023 Filed May 22, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,695 | $490.77 | $831,858.37 |
DisclosureSEC source: 0000874716-23-000086 · wf-form4_168478920867596.xml · nonDerivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,337 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $490.375 to a high of $491.30 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 18, 2023 Filed May 22, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,242 | $489.71 | $1,097,925.56 |
DisclosureSEC source: 0000874716-23-000086 · wf-form4_168478920867596.xml · nonDerivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,032 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $489.32 to a high of $490.32 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 18, 2023 Filed May 22, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,012 | $488.63 | $494,497.91 |
DisclosureSEC source: 0000874716-23-000086 · wf-form4_168478920867596.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,274 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $488.21 to a high of $489.02 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 18, 2023 Filed May 22, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,753 | $487.84 | $1,343,010.58 |
DisclosureSEC source: 0000874716-23-000086 · wf-form4_168478920867596.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,286 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $487.19 to a high of $488.19 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 18, 2023 Filed May 22, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,000 | $486.48 | $486,482.00 |
DisclosureSEC source: 0000874716-23-000086 · wf-form4_168478920867596.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,039 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $486.08 to a high of $487.03 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 18, 2023 Filed May 22, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 10,000 | $79.54 | $795,400.00 |
DisclosureSEC source: 0000874716-23-000086 · wf-form4_168478920867596.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2023 Filed May 19, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 257 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000874716-23-000075 · wf-form4_168453000585614.xml · derivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257 Underlying: Common Stock · 257 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier. F2 · price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 17, 2023 Filed May 19, 2023 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 645 | $0.00 Strike: $487.12 | $0.00 |
DisclosureSEC source: 0000874716-23-000075 · wf-form4_168453000585614.xml · derivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 645 Underlying: Common Stock · 645 shares Expires 2033-05-16 F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 15, 2023 Filed May 17, 2023 21:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 3,514 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-23-000062 · wf-form4_168435733418858.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,039 Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 344 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000874716-23-000052 · wf-form4_168418625435211.xml · derivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 344 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event was earlier. F3 · price: Not applicable. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event was earlier. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event was earlier. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 344 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-23-000052 · wf-form4_168418625435211.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,553 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,685 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-23-000052 · wf-form4_168418625435211.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2023 Filed May 11, 2023 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 560 | Not disclosed Strike: $178.26 | Not disclosed |
DisclosureSEC source: 0000874716-23-000045 · wf-form4_168383885791613.xml · derivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 560 shares Expires 2028-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that became exercisable on the fifth anniversary of the date of grant. Read SEC document |
| May 10, 2023 Filed May 11, 2023 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 560 | $178.26 | $99,825.60 |
DisclosureSEC source: 0000874716-23-000045 · wf-form4_168383885791613.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2023 Filed May 11, 2023 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 1,685 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-23-000045 · wf-form4_168383885791613.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,334 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.